SCHEMBL9963308

SCHEMBL9963308

COc1ccc2c(c1)C(=O)CC1(CCN(C(C)C)CC1)S2(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
KLK7 P49862 1/20 0.38
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
MMP1 P03956 3/20 0.36
MMP9 P14780 3/20 0.36
MMP13 P45452 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
HTT P42858 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963314 0.81 CYP2D6 (0.41) KDM4EMAPTALDH1A1SMN1; SMN2HTR2C
SCHEMBL9963305 0.72 RYR2 (0.40) KDM4EKLK7MAPTTP53POLB
SCHEMBL9963319 0.72 CYP2D6 (0.33)
SCHEMBL13340002 0.67 KDM4E (0.39) KDM4EHTTALDH1A1HTR2CHTR2A
SCHEMBL9963148 0.66 KDM4E (0.53) KDM4EKLK7HTTCYP1A2ALDH1A1
Hydrochloric Acid SCHEMBL3494624 0.66 KDM4E (0.38) KDM4EHTTALDH1A1HTR2CHTR2A
SCHEMBL24878794 0.65 DRD1 (0.43) MAPTMMP1MMP9MMP13DRD2
SCHEMBL16624014 0.65 METAP1 (0.44) KDM4EPDE3BPDE3AHTTCYP1A2
SCHEMBL9963316 0.63 SIGMAR1 (0.60) SMN1; SMN2HTR2CHTR2AHTR2BDRD2
SCHEMBL14112072 0.62 HRH3 (0.51) ALDH1A1SMN1; SMN2HTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 KDM4E 3804/4885KLK7 2327/4885MAPT 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.